Immatics (NASDAQ:IMTX) is Vestal Point Capital LP’s 9th Largest Position

Vestal Point Capital LP increased its position in shares of Immatics (NASDAQ:IMTX) by 36.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,750,000 shares of the company’s stock after purchasing an additional 1,000,000 shares during the quarter. Immatics makes up about 3.2% of Vestal Point Capital LP’s holdings, making the stock its 9th biggest position. Vestal Point Capital LP owned approximately 3.14% of Immatics worth $42,788,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IMTX. Quarry LP bought a new stake in shares of Immatics during the 2nd quarter worth $99,000. Forefront Analytics LLC purchased a new stake in Immatics during the second quarter worth about $139,000. AlphaCentric Advisors LLC raised its position in Immatics by 14.3% in the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock worth $232,000 after acquiring an additional 2,500 shares during the period. Algert Global LLC purchased a new position in Immatics in the second quarter valued at about $242,000. Finally, XTX Topco Ltd bought a new position in shares of Immatics during the 2nd quarter valued at approximately $321,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group raised shares of Immatics to a “strong-buy” rating in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th. Bank of America cut their price target on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 19th. Finally, Piper Sandler initiated coverage on Immatics in a research note on Monday, October 7th. They issued an “overweight” rating and a $19.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $16.67.

Immatics Price Performance

Shares of IMTX stock opened at $7.91 on Friday. Immatics has a 1 year low of $7.46 and a 1 year high of $13.77. The company’s fifty day simple moving average is $9.54 and its two-hundred day simple moving average is $11.07.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.